修订后的美国肺炎球菌疫苗接种建议在65岁以下缺医少药少数族裔成人中的成本效果
该研究用马尔可夫模型模拟假设的50岁黑人队列(作为缺医少药少数族裔的替代)和非黑人队列,评估美国成人肺炎球菌疫苗接种建议的增量成本效果。结果显示,在50岁和65岁接种PCV15/PPSV23的公共卫生影响最大;当前基于风险的建议相比所有50岁人群普遍接种在经济和临床上均不利。
要点
- 在50岁和65岁接种PCV15/PPSV23的公共卫生影响最大。
- 黑人队列中,50岁接种PCV15/PPSV23相比50岁接种PCV20每获得一个QALY需104,723美元。
- 当前基于风险的建议在两个队列中均比其他策略更昂贵且效果更差。
核心结论
- 当前针对65岁以下成人的基于风险的美国成人肺炎球菌疫苗接种建议,在黑人队列和非黑人队列中相比所有50岁人群普遍接种,在经济和临床上均不利。
- 基于年龄的50岁肺炎球菌疫苗接种建议可能减少肺炎球菌疾病负担的不公平。
研究设计与样本
- 马尔可夫模型,检查假设的50岁黑人队列(作为缺医少药少数族裔的替代)和非黑人队列。
- 模型参数来自美国数据库、临床试验和德尔菲专家组。
- 队列从医疗保健视角终身随访,按每年3%贴现。
主要发现
- 在50岁和65岁接种PCV15/PPSV23的公共卫生影响最大。
- 黑人队列中,50岁接种PCV15/PPSV23相比50岁接种PCV20,每获得一个QALY需104,723美元。
- 黑人队列中,50岁和65岁接种PCV15/PPSV23相比50岁接种PCV15/PPSV23,每获得一个QALY需240,952美元。
- 当前建议的两个选项在两个队列中均比其他策略更昂贵且效果更差。
- 敏感性分析中,基于年龄的50岁或50/65岁接种PCV20或PCV15/PPSV23可能有利,取决于疫苗效力或疫苗摄取差异,而当前建议仍不利。
关键数值与推荐
- PCV15/PPSV23在50岁和65岁接种的公共卫生影响最大。
- 黑人队列中,50岁接种PCV15/PPSV23相比50岁接种PCV20的增量成本效果比为104,723美元/QALY。
- 黑人队列中,50岁和65岁接种PCV15/PPSV23相比50岁接种PCV15/PPSV23的增量成本效果比为240,952美元/QALY。
- 当前建议的两个选项在两个队列中均更昂贵且效果更差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 15- and 20-valent pneumococcal conjugate vaccines (PCV15/PCV20) were recently recommended for US adults, giving either PCV20 alone or PCV15 followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) to all 65 + -year-olds and to high-risk younger adults. However, general population recommendations to vaccinate all 50-year-olds could reduce racial pneumococcal disease disparities given greater risk in underserved minority populations. METHODS: A Markov model examining hypothetical 50-year-old Black cohorts (serving as a proxy for underserved minorities) and non-Black cohorts estimated the incremental cost effectiveness of US adult pneumococcal vaccination recommendations compared to PCV20 or PCV15/PPSV23 for all 50-year-olds with no vaccination thereafter, or PCV20 or PCV15/PPSV23 for all at ages 50 and 65 years (50/65). Model parameters came from US databases, clinical trials, and Delphi panels. Cohorts were followed over their lifetimes from a healthcare perspective discounted at 3 %/year. RESULTS: PCV15/PPSV23 given at ages 50/65 had greatest public health impact. In Black cohorts, PCV15/PPSV23 at age 50 cost $104,723/quality adjusted life year (QALY) gained compared to PCV20 at age 50, while PCV15/PPSV23 at 50/65 cost $240,952/QALY gained compared to PCV15/PPSV23 at age 50. Both current recommendation options were more expensive and less effective than other strategies in both cohorts. In sensitivity analyses, age-based PCV20 or PCV15/PPSV23 use at ages 50 or 50/65 could be favorable depending on vaccine effectiveness or differential vaccine uptake, while current recommendations remained unfavorable. CONCLUSION: Recent risk-based US adult pneumococcal vaccination recommendations for adults < 65-years-old, were economically and clinically unfavorable compared to general population vaccination of all 50-year-olds in Black and non-Black cohorts. An age-based pneumococcal vaccination recommendation at age 50 years may reduce inequities in pneumococcal disease burden.
引用
- Wateska AR, Patricia Nowalk M, Lin CJ, et al. Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old. Vaccine. 2022. PMID: 36336526. doi:10.1016/j.vaccine.2022.10.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。